SOPHiA GENETICS S.A.
NASDAQ:SOPHMedical - Healthcare Information Services
+$0.02 today
- Market cap
- $635.90M
- Beta
- 0.98
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.14
Volume 0.61M
Average 0.10M
SOPH Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
SOPHiA GENETICS S.A.NASDAQ: SOPH
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 33.8% from a year ago
Net receivables stood at $14.31M at the end of Q1 FY2026, up 33.8% from a year earlier and down 22.8% from the prior quarter. Over 3 fiscal years it compounded at +32.0% a year.
Context
- Net receivables amounted to 9.1% of total assets at the end of Q1 FY2026, up 1.8 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +33.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 18.53M USD
- Year-over-year change
- +113.2%
- 4-year CAGR
- +27.1%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.53M | +113.2% |
| FY2024 | 2024-12-31 | 8.69M | -42.8% |
| FY2023 | 2023-12-31 | 15.21M | +88.8% |
| FY2022 | 2022-12-31 | 8.05M | +13.6% |
| FY2021 | 2021-12-31 | 7.09M | — |
Net Receivables vs competitors
How SOPH compares with its peers on the latest reported figures
- SOPH's Mar 2026 net receivables of $14.31M is the 8th highest of the 10 companies compared; the peer median is $43.44M.
- Its year-over-year change of +33.8% is the 2nd highest of 10, against a peer median of +2.3%.
- Net receivables amounts to 9.1% of total assets for SOPH, versus a peer median of 8.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $380.74M | +31.6% | +53.4% | 15.5% | |
| Mar 2026 | $107.61M | +2.3% | +9.4% | 7.2% | |
BLLNBillionToOne, Inc. | Jun 2026 | $74.89M | +146.1% | — | 10.3% |
| Mar 2026 | $59.15M | -7.7% | +7.2% | 14.3% | |
| Mar 2026 | $43.44M | +20.4% | -3.0% | 8.2% | |
| Mar 2026 | $39.36M | -8.3% | -4.0% | 7.6% | |
| Mar 2026 | $32.86M | +0.1% | +19.4% | 19.6% | |
| Mar 2026 | $14.31M | +33.8% | +32.0% | 9.1% | |
| Mar 2026 | $13.02M | +18.7% | -0.9% | 4.0% | |
| Mar 2026 | $11.31M | -1.3% | -8.7% | 8.4% | |
| Peer median (excluding SOPH) | $43.44M | +2.3% | +3.2% | 8.4% | |
Competitors are the stored peer set for SOPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 192.96M | 161.31M | 123.25M | 80.23M | 70.29M |
| Short-term Investments | 72.36M | 17.31M | 0 | 0 | 0 |
| Net Receivables | 7.09M | 8.05M | 15.21M | 8.69M | 18.53M |
| Inventory | 5.73M | 5.16M | 6.48M | 5.87M | 6.35M |
| Other Current Assets | 775K | 731K | 345K | 835K | 758K |
| Total Current Assets | 282.86M | 196.26M | 148.05M | 99.41M | 99.08M |
| Property, Plant & Equipment (Net) | 15.96M | 21.4M | 23.1M | 19.38M | 18.05M |
| Goodwill | 8.3M | 8.19M | 9M | 8.34M | 9.56M |
| Intangible Assets | 7.38M | 11.78M | 18.19M | 20.66M | 26.34M |
| Long-term Investments | 0 | 0 | 0 | 0 | 1.98M |
| Tax Assets | 1.99M | 1.94M | 1.72M | 1.77M | 2.26M |
| Other Non-current Assets | 3.7M | 4.28M | 6.1M | 5.76M | 6.21M |
| Total Non-current Assets | 37.32M | 47.58M | 58.11M | 55.9M | 64.38M |
| Total Assets | 320.17M | 243.84M | 206.16M | 155.31M | 163.46M |
| Account Payables | 2.34M | 2.17M | 2.26M | 1.93M | 5.32M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 891K | 356K | 769K | 658K | 0 |
| Deferred Revenue | 4.07M | 3.43M | 9.49M | 5.73M | 16.72M |
| Other Current Liabilities | 9.16M | 10.27M | 13.58M | 11.23M | 1.68M |
| Total Current Liabilities | 28.6M | 26.81M | 35.62M | 26.8M | 50.53M |
| Long-term Debt | 0 | 0 | 0 | 13.24M | 47.73M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 424K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.92M | 2.85M | 3.42M | 4.18M | 5.04M |
| Total Non-current Liabilities | 16.17M | 16.9M | 19.09M | 32.02M | 65.78M |
| Total Liabilities | 44.77M | 43.71M | 54.71M | 58.82M | 116.31M |
| Common Stock | 3.33M | 3.46M | 4.05M | 4.19M | 4.81M |
| Retained Earnings | (211.35M) | (298.8M) | (377.78M) | (440.28M) | (519.28M) |
| Accumulated OCI | 12.54M | 23.96M | 53.98M | 61.04M | 89.15M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 275.4M | 200.13M | 151.44M | 96.49M | 47.15M |
| Total Debt | 13.06M | 16.74M | 18.6M | 30.03M | 63.02M |
| Net Debt | (179.9M) | (144.56M) | (104.65M) | (50.2M) | (7.27M) |
SOPHiA GENETICS S.A.
NASDAQ:SOPH
Intrinsic Alpha fair value
Locked
Current Price
$7.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.